
|Articles|February 26, 2010
Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9
Advertisement
Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9
Purpose: To assess the 1-year functional outcome and to evaluate the morphological changes after intravitreal injections of ranibizumab in eyes affected with retinal angiomatous proliferation (RAP) due to age-related macular degeneration (AMD).
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
3
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
4
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
5













































